AJP - Heart Track the topics, authors and articles important to you
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
 QUICK SEARCH:   [advanced]


     


Am J Physiol Heart Circ Physiol (February 23, 2007). doi:10.1152/ajpheart.01354.2006
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
292/6/H3158    most recent
01354.2006v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (7)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bulhak, A. A
Right arrow Articles by Pernow, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bulhak, A. A
Right arrow Articles by Pernow, J.
Submitted on December 12, 2006
Accepted on February 20, 2007

The cardioprotective effect of rosuvastatin in vivo is dependent on inhibition of geranylgeranyl pyrophosphate and altered RhoA membrane translocation

Aliaksandr A Bulhak1*, Joy Roy2, Ulf Hedin2, Per-Ove Sjoquist3, and John Pernow3

1 Department of Medicine, Cardiology Unit, Karolinska Institute, Stockholm, Sweden
2 Department of Molecular Medicine and Surgery, Karolinska Institute, Stockholm, Sweden; Stockholm, Sweden
3 Stockholm, Sweden; Department of Medicine, Cardiology Unit, Karolinska Institute, Stockholm, Sweden

* To whom correspondence should be addressed. E-mail: aliaksandr.bulhak{at}ki.se.

Background: HMG-CoA reductase inhibitors (statins) protect the myocardium against ischemia/reperfusion injury via a mechanism unrelated to cholesterol-lowering. Statins may inhibit isoprenylation and thereby prevent activation of proteins such as RhoA. We hypothesized that statins protect the myocardium against ischemia/reperfusion injury via mechanism involving inhibition of geranylgeranyl pyrophosphate synthesis and translocation of RhoA to the plasma membrane. Methods: Sprague-Dawley rats were given either the HMG-CoA reductase inhibitor rosuvastatin, geranylgeranyl pyrophosphate dissolved in methanol, the combination of rosuvastatin and geranylgeranyl pyrophosphate, rosuvastatin and methanol, or distilled water (control) by intraperitoneal injection for 48 h before ischemia/reperfusion. Animals were anesthetized and either subjected to 30 min of coronary artery occlusion followed by 2 h of reperfusion whereat infarct size was determined, or the expression of RhoA protein was determined in cytosolic and membrane fractions of non-ishemic myocardium. Results: There were no significant differences in hemodynamics between the control group and the other groups before ischemia or during ischemia and reperfusion. The infarct size was 80±3% of the area at risk in the control group. Rosuvastatin reduced infarct size to 64±2% (p<0.001 vs. control). Addition of geranylgeranyl pyrophosphate (77±2%, p<0.01 vs. rosuvastatin) but not methanol (65±2% in the, ns vs. rosuvastatin) abolished the cardioprotective effect of rosuvastatin. Geranylgeranyl pyrophosphate alone did not affect infarct size per se (84±2%). Rosuvastatin increased the cytosol/membrane ratio of RhoA protein in the myocardium (p<0.05 vs. control). These changes were abolished by addition of geranylgeranyl pyrophosphate. Conclusions: The cardioprotection and the increase of RhoA cytosol/membrane ratio induced by rosuvastatin in vivo are blocked by geranylgeranyl pyrophosphate. The inhibition of geranylgeranyl pyrophosphate formation and subsequent modulation of cytosol/membrane-bound RhoA are of importance for the protective effect of statins against myocardial ischemia/reperfusion injury.




This article has been cited by other articles:


Home page
Cardiovasc ResHome page
C. Jung, A. T. Gonon, P.-O. Sjoquist, J. O. Lundberg, and J. Pernow
Arginase inhibition mediates cardioprotection during ischaemia-reperfusion
Cardiovasc Res, September 18, 2009; (2009) cvp303v2.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
P. Meijer, W. J.G. Oyen, D. Dekker, P. H.H. van den Broek, C. W. Wouters, O. C. Boerman, G. J. Scheffer, P. Smits, and G. A. Rongen
Rosuvastatin Increases Extracellular Adenosine Formation in Humans In Vivo: A New Perspective on Cardiovascular Protection
Arterioscler Thromb Vasc Biol, June 1, 2009; 29(6): 963 - 968.
[Abstract] [Full Text] [PDF]


Home page
J CARDIOVASC PHARMACOL THERHome page
M. S. Kostapanos, H. J. Milionis, and M. S. Elisaf
An Overview of the Extra-Lipid Effects of Rosuvastatin
Journal of Cardiovascular Pharmacology and Therapeutics, September 1, 2008; 13(3): 157 - 174.
[Abstract] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Visit Other APS Journals Online
Copyright © 1977 by the American Physiological Society.